At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands) discusses the investigational approaches of brentuximab vedotin, an anti-CD30 antibody conjugated to a cytostatic microtubule-disrupting agent, in the treatment of previously untreated and refractory/relapse patients with Hodgkin lymphoma.